Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Zentalis Pharmaceuticals, Inc. (ZNTL) had Stock-Based Compensation of $20.72M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-35.22M |
|
-- |
|
-- |
|
$37.39M |
|
$-37.39M |
|
$2.62M |
|
$-34.77M |
|
$-34.77M |
|
$-35.22M |
|
$-35.22M |
|
$-35.22M |
|
$-35.22M |
|
$-37.39M |
|
$-37.67M |
|
71.87M |
|
71.87M |
|
$-0.50 |
|
$-0.50 |
|
| Balance Sheet Financials | |
$253.19M |
|
$2.77M |
|
$35.78M |
|
$288.97M |
|
$36.56M |
|
-- |
|
$36.20M |
|
$72.76M |
|
$216.20M |
|
$216.20M |
|
$216.20M |
|
69.09M |
|
| Cash Flow Statement Financials | |
$-125.25M |
|
$131.62M |
|
$-4.28M |
|
$36.53M |
|
$38.62M |
|
$2.09M |
|
|
Stock-Based Compensation |
$20.72M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.93 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-124.55M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-16.29% |
|
-16.29% |
|
-12.19% |
|
-16.29% |
|
$3.13 |
|
$-1.73 |
|
$-1.74 |
|